Alphamab Oncology (HK:9966) has released an update.
Alphamab Oncology has presented promising research updates on its innovative drug, JSKN033, at SITC 2024, highlighting its potential in treating advanced HER2-expressing solid tumors. The phase I/II clinical trial showed an 80% disease control rate, with a favorable safety profile among the participants. This advancement underscores Alphamab’s progress in developing cutting-edge cancer therapies, potentially boosting investor confidence in its stock.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Stock Market News Today, 11/11/24 – Futures Trend Higher After the Election Week Rally
- Upcoming Stock Splits This Week (November 11 to November 15) – Stay Invested
- U.S. Orders Taiwan Semi to Stop Suppling Advanced AI Chips to China
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
